In-Depth Look at GMP-Grade Chromatography Media: Why Antibody Capture Media are the 'Cost Bottleneck' of Biologics?

In the industrialization systems of biologics such as monoclonal antibodies, bispecific antibodies, and fusion proteins, the purification process directly determines the purity, safety, and mass production costs of the drugs. It is a core step in controlling drug quality. According to industry research reports, the cost of downstream purification in biologics usually accounts for 40%–80% of the total production cost (with significant differences depending on the process and product type). As the first key step in the purification process, capture chromatography media play a crucial role in enriching the target protein, initially removing impurities, and exchanging the sample buffer system. They are the "first gate" in the biologics purification chain.

Among them, GMP-grade chromatography media have become a must-have for commercial biologics production due to their compliance, stability, and traceability. And antibody capture media, as a specialized category, are even more essential consumables for large-scale monoclonal antibody production. This article will dive into the technical definitions, key parameters, and process value of three core types of media. Combined with AI-driven process empowerment, it will explain their core significance in the standardized mass production of biologics.

I. Clearing up the concepts: Definitions and niche positioning of the three core types of media

Hierarchical relationships among the three types of chromatographic packing materials

In biopharmaceutical chromatography process systems, GMP-grade chromatography packers, capture chromatography packers, and antibody capture packers all follow a hierarchical structure of general substrate—functional category—specialized niche, with clear conceptual boundaries and precise process positioning, serving as the core foundational material for biological purification processes.

1. Capture chromatography packing: the core pre-carrier of the purification process

Capture chromatography packing is a specialized chromatography medium designed for the capture stage of biological macromolecule purification. Its core function is to rapidly enrich target products from the complex cell culture supernatant, remove most host cell proteins (HCP), nucleic acids, endotoxins, and other impurities, while simultaneously completing sample concentration and buffer displacement, thereby reducing the burden on subsequent purification steps.

Compared to purified packers, capture chromatography packings focus more on high loading, high flow rate, high fault tolerance, and contamination resistance. They are suitable for handling large-scale, large-volume, and high-impurity crude samples, and are the core prerequisite for efficient mass production of biopharmaceuticals. They are widely used in the primary purification of various biological products such as antibodies, recombinant proteins, and vaccine proteins.

2. Antibody Capture Packing: Specialized sub-media for monoclonal antibody drugs

Antibody capture fillers are a core subcategory of capture chromatography fillers, specifically tailored to the purification needs of IgG monoclonal antibodies, polyclonal antibodies, and Fc fusion proteins. The industry mainstream focuses on recombinant Protein A affinity fillers. Its core principle relies on the specific binding of the Protein A ligand to the antibody Fc segment, enabling precise antibody capture, characterized by strong specificity, high enrichment efficiency, and high one-step purification multiplier.

Mature process data show that high-quality antibody capture packers can achieve antibody purity exceeding 90% after one-step capture, significantly reducing the purification pressure of subsequent ion exchange and hydrophobic chromatography, making them the preferred core consumable for industrialized purification of antibody drugs.

3. GMP-grade chromatography fillers: mandatory standards for industrial compliance and compliance

GMP-grade chromatography fillers are not independent functional categories, but standardized chromatography fillers that comply with Good Manufacturing Practice (Good Manufacturing Practice) and are essential for biopharmaceuticals to move from laboratory R&D to commercial mass production.

Unlike laboratory research-grade fillers, GMP-grade fillers feature a complete quality control system, traceable documentation, and process validation data, strictly controlling key indicators such as ligand detachment, microsphere damage, impurity residues, and endotoxin content, fully meeting the review requirements of mainstream regulatory agencies such as NMPA (National Medical Products Administration), FDA (U.S. Food and Drug Administration), and EMA (European Medicines Agency).

Simply put, capture chromatography packers and antibody capture packings can be divided into research-grade and GMP-grade. GMP-grade packers are the mandatory standard for large-scale production of commercial drugs and are the core foundation for ensuring stable drug quality and compliant processes.

Understanding these three concepts, let's take a closer look: What are the key hard metrics to evaluate whether a GMP-grade antibody capture filler is good? Where is domestic filler stuck now? What role can AI play in this?

II. Core Technical Parameters: The Hard-Core Metrics of Industrial-Grade Media

GMP antibody capture media designed for large-scale antibody drug production comes with strict quantitative technical specifications that directly affect production efficiency and drug quality. The three types of media each focus on different technical aspects—capture chromatography media emphasize high binding capacity and fast flow rates, antibody capture media focus on specificity and purity, and GMP chromatography media place higher demands on batch consistency and compliance. All core parameters follow the common standards of the biopharmaceutical industry:

1. Dynamic Binding Capacity (DBC): The Key Metric for Production Capacity

Under a standard retention time of 4-6 minutes, high-quality GMP-grade antibody capture media can achieve a human IgG DBC of 60-80 mg/mL, which is the mainstream level for the new generation of alkali-tolerant Protein A media internationally. The higher the capacity, the more sample can be processed per batch, reducing the amount of media and column equipment needed, and significantly lowering production costs.

2. Alkali Stability (CIP Resistance): A Critical Variable for Longevity

Able to withstand 0.5-1.0 M NaOH for in-place cleaning, compatible with industrial standard CIP (Clean-In-Place) processes, effectively removing residual host proteins, endotoxins, and microbial contaminants between batches. Common industry standards state: using 0.5 M NaOH for CIP, with 15 minutes of alkali contact each time, after 100 complete CIP cycles, the DBC retention rate remains above 90%, significantly reducing material replacement frequency and downtime costs.

3. Flow Rate and Pressure Compatibility: Guaranteeing Production Efficiency

Standard operating flow rates range from 100-500 cm/h; rigid polymer-based media can tolerate pressures up to 0.5 MPa, while highly cross-linked agarose media can withstand up to 0.3 MPa. High pressure tolerance and low compressibility make them suitable for high-speed production, shorten purification cycles per batch, and improve overall production line throughput.

4. Product Quality Control Metrics: The Baseline for GMP Compliance

Under GMP, key metrics like ligand residuals in the media, batch-to-batch performance variation, and endotoxin content are strictly controlled within industry-standard ranges, effectively preventing quality risks caused by media impurities and ensuring finished antibody products meet critical quality attributes such as HCP, aggregates, and host DNA levels.

III. Industry Pain Points: Why Are Domestic GMP Fillers Stuck at the Door to Commercialization?

In antibody drug production costs, downstream purification accounts for about 30%-50% of total production costs, while Protein A affinity chromatography alone accounts for 50%-70% of the downstream purification cost in the first step. In other words, a single tiny packing column consumed about 20% of the production cost of the entire antibody drug.

There are several sets of data behind this that are worth noting:

In terms of market size, according to QYResearch statistics, global sales of chromatography fillers will reach $1.951 billion by 2025 and are expected to increase to $3.212 billion by 2032, with a compound annual growth rate (CAGR) of 7.4%. According to data from DIResearch, the global chromatography resin market size will reach $1.929 billion by 2025 and is expected to reach $3.015 billion by 2032. According to QYResearch data, global Protein A affinity chromatography media sales will reach $162 million by 2025 and are expected to reach $320 million by 2031. In China, according to data from Qianzhan Industry Research Institute, the domestic biopharmaceutical chromatography media market size will reach 10.8 billion yuan by 2025 and is expected to reach 13.2 billion yuan by 2026, leading the world in growth rate.

Looking at the localization rate, the situation is even more worth pondering. According to industry research, the market size for chromatography fillers in China is about 6 to 7 billion yuan, but domestic brands hold less than 20% market share. High-end alkali-resistant affinity ligands remain highly dependent on imports and are one of the most prominent "bottleneck" links in the biopharmaceutical supply chain.

Why are domestic fillers good in clinical stages, but fail to rise once commercialized? The core is stuck in three places:

First, the performance barriers of ligand proteins. The core properties of Protein A fillers are determined by the combination of ligand proteins and microsphere matrix. Among these, the binding capacity, alkali resistance, shedding rate, and specificity of the ligands are important technical barriers for high-end fillers. Natural Protein A rapidly deactivates under 1M NaOH conditions, and industrial production requires fillers to withstand repeated CIP (in-situ washes), necessitating complex engineering modifications of ligand proteins.

Second, engineering barriers to batch stability. GMP production has extremely stringent requirements for packing batch consistency. From the fermentation, expression, and purification of ligand proteins to the preparation of microsphere matrices and the coupling process, even the slightest fluctuation in any one stage can lead to performance drift in the packing material. Once a pharmaceutical company locks onto a certain filler in the marketing process, switching suppliers requires re-process validation, which is extremely costly and time-consuming.

Third, regulatory compliance system barriers. For fillers used in commercial production, suppliers must provide complete regulatory support documents, including raw material traceability, production process validation, stability data, and studies of extractable/leachable substances. Building this quality system often requires years and extensive project accumulation.

Even a slight improvement in the lifespan and loading capacity of packing materials can translate into significant cost advantages in large-scale production. This is why pharmaceutical companies are extremely cautious when choosing packing materials—they’re not unwilling to switch to domestic options, they just dare not change easily.

IV. AI Platform Empowerment: MatwingsVenus™ (Xiaowu™) helps ensure precise implementation of packing material processes

 Closed-loop diagram of the full AI ligand development workflow

Facing the challenges mentioned above, the traditional "trial-and-error" approach to protein engineering is gradually being replaced by AI-driven rational design. 

Chromatography media consists of two parts: the bead matrix (hardware) and the ligand protein (software). Domestic bead production has caught up in the preparation of microspheres, but ligand design is the real differentiator for high-end media. Ligands are essentially functional proteins, which just happens to be the area where large protein models excel. 

Shanghai Matwings Technology's AI-driven protein R&D platform, MatwingsVenus™ (Xiaowu™), is applying this methodology to the field of consumable chromatography media. The core logic is: since the performance of media is determined by the ligand protein, why not introduce AI large models in the ligand design stage to break performance bottlenecks from the very beginning? 

Specifically, the MatwingsVenus™ (Xiaowu™) media R&D system is built on three layers of capability. 

Layer 1: Ultra-large-scale protein data base MatwingsVenus™ Pod 

The platform has cleaned and integrated 15 billion protein sequences worldwide, including 6.5 billion high-quality sequences labeled with environmental factors like temperature and pH. These data don't just cover conventional bioinformation but also include sequences from extreme environments like deep sea or volcanoes, featuring acid/base and heat-resistant proteins, providing rich "evolutionary material" for improving ligand protein alkali tolerance and stability.

Layer 2: AI ligand design capability MatwingsVenus™ Large Model 

Based on its self-developed general protein design large model, the platform can perform multi-objective optimization for ligand proteins—taking into account loading capacity, alkali resistance, specificity, elution conditions, expression level, and more. Traditional directed evolution requires constructing massive mutant libraries and high-throughput screening, which can take 2-5 years, while AI-driven multi-objective optimization can shrink this timeline to just a few months. 

For example, Protein A ligands easily undergo deamidation of Asn residues and peptide bond hydrolysis under high-concentration NaOH, leading to inactivation. AI design rationally replaces sensitive surface residues while optimizing overall folding stability, producing recombinant Protein A ligands that can withstand routine 1M NaOH cleaning and regeneration. After multiple cycles, dynamic binding capacity shows no obvious decay, effectively extending media lifespan. Meanwhile, ligand protein purity remains above 95%, with host cell proteins (HCP), endotoxins, nucleic acids, and other impurities strictly controlled within pharmacopeia standards. 

In another project modifying single-domain antibody ligands, AI design also demonstrated remarkable efficiency: alkali tolerance increased fourfold, nearly doubling media lifespan. For novel molecules like bispecific antibodies that require mild elution, AI can also design ligands suitable for higher pH elution, avoiding acid-induced aggregation caused by low-pH elution.

Level 3: GMP-Level Industrial Implementation Capability

High-quality ligand proteins designed with AI have already achieved GMP-level scalable production. They strictly follow standardized quality control systems and show strong batch-to-batch consistency. At the same time, they support customized specifications, offering products from small lab trials to industrial-scale production, ensuring long-term, stable supply for customers.

This 'AI-designed ligands + standardized production' model essentially shifts the logic of developing capture chromatography resins from 'make first, test performance later' trial-and-error experience to 'define requirements first, then design molecules' precise engineering — which is exactly the key path for achieving domestic substitution of high-end bio-consumables.

V. Industry Outlook

As China's biopharmaceutical industry continues to upgrade, the refinement, intelligence, and cost reduction of downstream purification processes are becoming the core competitive factors. GMP-grade capture chromatography resins and antibody capture resins, as essential core consumables, are evolving toward ultra-high loading, ultra-long lifespan, strong contamination resistance, and high adaptability.

An even more notable trend is that with the surge of new molecules like bispecific antibodies, ADCs, and nanobodies, capture chromatography resins are moving from a 'one resin fits all' standardized era to a 'customized ligand + personalized process' precision era. The efficiency of developing customized ligands is exactly where AI large models can bring the most value.

From catching up on microsphere matrices, to running alongside in ligand proteins, and now leading in AI design, domestic GMP-grade chromatography resins are carving out a 'bottom-up' comeback path. When ligand design no longer relies on manpower-intensive high-throughput screening but becomes AI-driven precise engineering, this 'hidden chip' of China's biopharmaceutical supply chain has the potential to overtake in the next generation of technological iteration.

The MatwingsVenus™ (XiaoWu™) platform will continue leveraging algorithmic and data advantages to connect the entire chain of 'resin selection — process optimization — production validation,' providing professional and intelligent purification solutions for domestic biopharmaceutical companies, supporting high-quality and large-scale development of China's biopharmaceutical industry.